Trial
NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
Condition
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Intervention
Abemaciclib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-04